HIV InfectionsNCT00002022
Treatment Program for Anemia in AIDS Patients
A study testing Epoetin alfa in people with HIV Infections and Cytopenias, run by R W Johnson Pharmaceutical Research Institute at 1 site in United States.
Trial summary
The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients. Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- HIV Infections, Cytopenias
- What is being tested?
- Epoetin alfa
- How many people
- Not given
- Where
- 1 siteUnited States
- Study dates
- Start not givento not given
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- Co-existing Condition:
- Patients with the following are excluded:
- Life expectancy < 3 months.
- = or < grade 4 performance score.
- AIDS-related dementia.
- Uncontrolled hypertension.
Show all 19Show fewer
- Acute symptomatic opportunistic infection or other AIDS-defining illness.
- Patients with the following are excluded:
- Life expectancy < 3 months.
- = or < grade 4 performance score.
- AIDS-related dementia.
- Uncontrolled hypertension.
- Acute symptomatic opportunistic infection or other AIDS-defining illness.
- Patients must have:
- A clinical diagnosis of AIDS.
- Hematocrit < 30 percent.
- Endogenous serum erythropoietin level = or < 500 U/ml.
- A life expectancy = or > 3 months.
- > Grade 4 performance score.
Trial locations and contacts
1 site in 1 country.
United States1 site
R W Johnson Pharmaceutical Research Institute
Raritan, New Jersey, 088690602
About this study
The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.
- Conditions
- HIV Infections, Cytopenias
- Being tested
- Epoetin alfa
- Keywords
- Recombinant Proteins, Drugs, Investigational, Erythropoietin, Acquired Immunodeficiency Syndrome, Anemia, Zidovudine
- Medical subject headings
- HIV Infections, Cytopenia, Acquired Immunodeficiency Syndrome, Anemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Epoetin alfaDrug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2001 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
Sponsor and investigators
- Lead sponsor
- R W Johnson Pharmaceutical Research Institute
- Sponsor type
- Industry (pharma, biotech, devices)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00002022
- Sponsor's protocol ID
- 004G
- Other IDs
- I88-083
- Status last verified
- Feb 1991
- First submitted
- 2 Nov 1999
- Last updated
- 24 Jun 2005
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2005. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Treatment Program for Anemia in AIDS Patients
- ClinicalTrials.gov ID
- NCT00002022
- Acronym / sponsor ID
- 004G
- Conditions
- HIV Infections, Cytopenias
- Keywords
- Recombinant Proteins, Drugs, Investigational, Erythropoietin, Acquired Immunodeficiency Syndrome, Anemia, Zidovudine
- Study type
- Interventional
- Recruitment status
- Completed
- Lead sponsor
- R W Johnson Pharmaceutical Research InstituteIndustry (pharma, biotech, devices)
- First posted
- 31 Aug 2001 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.
Study design
- Primary purpose
- Treatment
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (19 listed)
- Life expectancy < 3 months.
- = or < grade 4 performance score.
- AIDS-related dementia.
- Uncontrolled hypertension.
- Acute symptomatic opportunistic infection or other AIDS-defining illness.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Epoetin alfa | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2005.
Related trials for HIV Infections
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Not yet recruiting
Adapting the ESTEEM Intervention to Improve Mental Health and PrEP Uptake Among Men at Risk of HIV
PrEP Use
RecruitingPhase 2
Evaluating the Safety and Immunogenicity of MTBVAC
HIV I Infection, Tuberculosis
Active, not recruiting
Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men
HIV Infections, STI
Not yet recruiting
PNF RCT to Decrease Alcohol Use and Increase HIV Prevention
HIV (Human Immunodeficiency Virus), Alcohol Misuse
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Epoetin alfa in people with HIV Infections and Cytopenias, run by R W Johnson Pharmaceutical Research Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jun 2005. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2005.